Abstract
In the last couple of years, several extended half-life factor VIII and factor IX preparations were intensively studied and gained approval. In order to extend half-lives, techniques like fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification are implemented. With these techniques, it is possible to extend half-lives of factor IX products 4- to 6- fold, while half-life extension of factor VIII products is limited to 1.5- to 2-fold due to their interaction with von Willebrand factor. Nevertheless, both extended half-life factor VIII and IX products have improved and facilitated prophylactic factor replacement therapy in hemophilia A and B, respectively. Extended half-life factor concentrates pose challenges to coagulation laboratories because accurate therapy monitoring is not possible with all factor activity assays currently used.
Citations
Mar 1, 2019·Therapeutic Drug Monitoring·Tim PreijersRon A A Mathôt
Apr 24, 2019·The Journal of Pharmacology and Experimental Therapeutics·A R Satvik IyengarAbhay H Pande
Aug 25, 2019·Blood·Amy D ShapiroJohannes Oldenburg
Dec 7, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Amanda B PayneConnie H Miller
Feb 6, 2020·Journal of Managed Care & Specialty Pharmacy·Mindy L SimpsonSongkai Yan
Mar 3, 2020·Journal of Thrombosis and Haemostasis : JTH·Flora PeyvandiMichael Spannagl
Aug 29, 2020·Journal of Managed Care & Specialty Pharmacy·Mindy L SimpsonSongkai Yan
Sep 17, 2020·Clinical Pharmacokinetics·Tim PreijersRon A A Mathôt
Sep 17, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Jun SuRonald Preblick
Mar 27, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Elena SantagostinoMacGregor Steele
Mar 19, 2019·Therapeutic Drug Monitoring·Tim PreijersRon A A Mathôt
Jun 7, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Katsuyuki FukutakeToshiyuki Karumori
Mar 23, 2019·Frontiers in Plant Science·Oguz TopRalf Reski
Sep 5, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Shannon L Meeks, Sébastien Lacroix-Desmazes
Sep 26, 2020·Annals of Hematology·Alexander SolmsToshko Lissitchkov
Dec 12, 2020·Blood Research·Eun Jin ChoiKayode Badejo
Jan 29, 2021·Thrombosis and Haemostasis·Laura H BukkemsRon A A Mathôt
Jan 15, 2021·Pharmaceuticals·Sacha ZeerlederIlse Jongerius
Feb 3, 2021·Journal of Thrombosis and Haemostasis : JTH·Haarin ChunAndrey G Sarafanov
Feb 25, 2021·European Journal of Clinical Pharmacology·Tim PreijersRon Mathôt
Dec 18, 2019·Molecular Therapy : the Journal of the American Society of Gene Therapy·John S S ButterfieldRadoslaw Kaczmarek
May 21, 2021·Journal of Thrombosis and Haemostasis : JTH·Olav VerslootUNKNOWN Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (IPSG)
Jun 23, 2021·Scientific Reports·Cihan AyIngrid Pabinger
Jul 23, 2021·BMJ Case Reports·Shireen I Alzadjali, Yasser Wali